Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2024-05-09 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It includes specifics about the authorized entrusted financial management, the amounts, types of financial products purchased, expected yields, investment directions, and risk control measures. The document is a disclosure of a significant transaction involving the use of idle raised funds for financial investment, meeting disclosure standards due to the amount exceeding 10% of audited net assets. It is not a financial report like an annual or interim report, nor is it a call transcript or management report. It is a regulatory announcement about capital use and financing activities related to raised funds. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing activity, not just a brief notice or report publication announcement.
2024-05-09 Chinese
2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2023 Annual General Meeting (AGM) resolution announcement for Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results on various proposals including the 2023 annual report, financial statements, budget, dividend plan, and other corporate matters. The document is a formal announcement of the resolutions passed at the AGM rather than the full annual report or financial statements themselves. It includes voting results and legal opinions confirming the validity of the meeting and resolutions. The content aligns with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the outcomes of shareholder votes at the AGM. The document length (5798 characters) and detailed voting results support this classification rather than a simple report publication announcement or the full annual report (10-K).
2024-04-28 Chinese
上海天璇律师事务所关于四川梓橦宫药业股份有限公司2023年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2023 Annual General Meeting (AGM) of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the legality and validity of the AGM's convening, attendance, voting procedures, and results. The document does not contain the actual annual report or financial statements but rather confirms the procedural compliance and voting outcomes of the AGM. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and validates the meeting procedures. The document length is about 4730 characters, which is sufficient for a detailed voting results announcement rather than a brief notice or a full annual report. Therefore, the appropriate classification is DVA with high confidence.
2024-04-28 Chinese
第四届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the supervisory board of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the convening and attendance of the fourth supervisory board's fourth meeting, and the approval of the 2024 first quarter report. The document references the actual 2024 first quarter report being disclosed separately on the Beijing Stock Exchange information platform (announcement 2024-053). The text itself does not contain the financial data or substantive analysis of the quarterly report but only the resolution approving it. The document length is short (827 characters) and serves as an announcement of the meeting resolution and report approval, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not an Interim/Quarterly Report (IR).
2024-04-25 Chinese
第四届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fourth meeting of the fourth board of directors of Sichuan Zitonggong Pharmaceutical Co., Ltd. It includes details about the meeting's convening, attendance, and the approval of the 2024 first quarter report. However, the document itself does not contain the actual financial statements or substantive financial data of the quarterly report; instead, it references that the full 2024 first quarter report was disclosed separately on the Beijing Stock Exchange information platform. The document is primarily about board meeting decisions and approvals, not the report itself. Therefore, it fits best under 'Board/Management Information' (MANG) as it announces board resolutions and management decisions rather than providing the full interim report or financial data.
2024-04-25 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "四川梓橦宫药业股份有限公司 2024 年第一季度报告" which translates to "Sichuan Zitonggong Pharmaceutical Co., Ltd. 2024 First Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the quarter ending March 31, 2024. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the first quarter of 2024. It is not an announcement of a report, but the report itself, and it is not an audit report since it states it is unaudited. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.